Navigation Links
Genzyme Begins Major Expansion of Boston Manufacturing Facility
Date:9/18/2007

00 square feet of new office and manufacturing-support space. Genzyme is also building a 26,000 square foot underground co-generation facility, which will generate steam to run the plant's process operations and will also produce electricity.

Genzyme began construction of Allston Landing in the early 1990s, and the facility was initially intended to produce one product -- Cerezyme(R) (imiglucerase for injection) for Type 1 Gaucher disease. While the physical size and layout of the facility have remained largely unchanged, Genzyme is now producing five products at the facility. Three are manufactured there: Cerezyme; Fabrazyme(R) (agalsidase beta) for Fabry disease; and Myozyme(R) (alglucosidase alfa) for Pompe disease. Genzyme also performs the filling and packaging for two products manufactured at other sites: Aldurazyme(R) (laronidase) for MPS I disease and Thyrogen(R) (thyrotropin alfa for injection), used in the screening of patients who have had thyroid cancer. Genzyme last expanded the site in 2004.

The Allston Landing facility is a highly visible landmark located between Storrow Drive and the Massachusetts Turnpike. The design and brick facade of the existing building establish a strong visual link to nearby universities. The expanded site has been designed to reflect a significantly more modern and transparent image, in keeping with Genzyme's continuing desire to embrace these qualities in its corporate culture. The design also will serve to symbolically open up the facility to the surrounding community.

The Allston expansion will incorporate environmentally responsible building practices similar to those used in Genzyme Center-the company's Cambridge headquarters-and its new Science Center in Framingham. Genzyme intends to seek certification for the expansion under the U.S. Green Building Council's LEED(R) (Leadership in Energy and Environmental Design) Green Building Rating System(TM).

The expanded facility will permanently house wo
'/>"/>

SOURCE Genzyme Corp.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Cytochroma settles lawsuit with Genzyme
2. Genzyme sues former Bone Care employees
3. Genzyme acquistion of Bone Care approved, significant impact forecast
4. DeForest biodiesel plant begins production
5. Deltanoid Pharmaceuticals begins phase II osteoporosis study
6. Prodesse begins clinical trials for flu virus detection
7. Closing the income gap begins with education
8. Corporate control begins with a strong board
9. Emerging game developer begins work on prototypes
10. GE begins human trials for cancer detection agent
11. Now the real work begins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... Boston, MA (PRWEB) May 22, 2013 ... convene in Alexandria, VA for the Oak ... 17th which will take place at the Hilton ... the Biodetection Technologies 2013 conference on ... Organizations Already Participating: , AdSave, American Elements, Applied ...
(Date:5/22/2013)... New York (PRWEB) May 22, 2013 ... the 3rd Annual Disruptive Innovations to Advance Clinical Trials ... Copley Plaza Hotel in Boston, MA. , Disruptive ... Janssen Pharmaceuticals and more share bold approaches to reduce ... , “Disruptive innovation needs to be big, or ...
(Date:5/22/2013)... 22, 2013  Superior Controls, Inc. has been ... Business NH Magazine.  For the past 22 years, ... distinguish themselves with extraordinary business and civic excellence. ... this honor," said Rick Pierro ... recognition, this award is a reflection of Superior ...
(Date:5/22/2013)... , May 22, 2013  Cleveland BioLabs, Inc. (NASDAQ: ... at the Second Annual Marcum LLP Microcap Conference, May 30, ... Neil Lyons , CPA, Chief Financial ... biodefense programs on May 30 at 1:30 p.m. Eastern Time.  ... be available on the Investors page of the Cleveland BioLabs ...
Breaking Biology Technology:Biodetection Technologies 2013 and Oak Ridge National Lab’s Biosurveillance Symposium to Bring Together Leading Organizations in Alexandria, VA from June 17-19, 2013 2Biodetection Technologies 2013 and Oak Ridge National Lab’s Biosurveillance Symposium to Bring Together Leading Organizations in Alexandria, VA from June 17-19, 2013 3Biodetection Technologies 2013 and Oak Ridge National Lab’s Biosurveillance Symposium to Bring Together Leading Organizations in Alexandria, VA from June 17-19, 2013 4Biodetection Technologies 2013 and Oak Ridge National Lab’s Biosurveillance Symposium to Bring Together Leading Organizations in Alexandria, VA from June 17-19, 2013 5Disruptive Innovation Hits Clinical Trials, Dedicated Event Launches 2Superior Controls of Seabrook, NH named Business of the Year for 2013 by Business NH Magazine 2Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference 2
... , MONROVIA, Calif., June 11 STAAR Surgical Company ... and marketer of minimally invasive ophthalmic products, today announced ... Epiphany Injector System for use with the Affinity(TM) Collamer(R) ... of the Epiphany will usher in a new era ...
... COLLEGEVILLE, Pa., June 11 New data from ... that Wyeth,s (NYSE: WYE ) investigational pneumococcal vaccine, ... potential to provide coverage against the 13 most prevalent serotypes ... death in children younger than five worldwide. , ...
... HONG KONG, June 11 /PRNewswire-Asia/ -- With ... week, Filligent, the Australian-led biotech company,is mobilizing stocks of ... A (H1N1) across Australia. The BioMask is the first ... seconds of contact while retaining,the breathability required by front-line ...
Cached Biology Technology:STAAR Surgical Receives FDA Clearance for the Epiphany(TM) Injector System 2STAAR Surgical Receives FDA Clearance for the Epiphany(TM) Injector System 3New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 2New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 3New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 4New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 5New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 6Australia: Face Mask That Kills Swine Flu Readied for Australian Pandemic Fight 2Australia: Face Mask That Kills Swine Flu Readied for Australian Pandemic Fight 3Australia: Face Mask That Kills Swine Flu Readied for Australian Pandemic Fight 4
(Date:5/23/2013)... wrapping of genomic DNA around nucleosomes in the ... A team of Ludwig-Maximilians-Universitaet (LMU) in Munich now ... be locally displaced from nucleosomes for transcription. , ... in the cell nucleus, wrapped around disk-shaped particles ... four different histone proteins and accommodating two loops ...
(Date:5/23/2013)... WASHINGTON Given the implications for the overall ... should play a primary role in ensuring that ... least 60 minutes per day of vigorous or ... the Institute of Medicine. Recent estimates suggest ... this evidence-based guideline for promoting better health and ...
(Date:5/23/2013)... or harsh treatments because science fails to identify ... the disease. Researchers at Case Western Reserve University ... that allows patients to safely choose to do ... drastic measures. , The project is one of ... engineering at Case Western Reserve and director of ...
Breaking Biology News(10 mins):Biochemistry: Unspooling DNA from nucleosomal disks 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3
... it turns out, children were not the only ones with ... past holiday season. In a new research report published in ... Biology ( http://www.jleukbio.org ), a team of scientists from ... Children show how a compound from licorice root (glycyrrhizin from ...
... biodegradable nanosized particles that can easily slip through ... deliver a sustained-release medication cargo. , The ... into harmless components, could one day carry life-saving ... conditions, including diseases of the eye, lung, gut ...
... study shows that a bacterial protein may help cocaine addicts ... bacterial enzyme that breaks down cocaine, thereby reducing its addictive ... for treatment of addiction has been limited by its short ... in the Journal of Pharmacology and Experimental Therapeutics ...
Cached Biology News:A trip to the candy store might help ward off rare, but deadly infections 2Biodegradable particles can bypass mucus, release drugs over time 2Biodegradable particles can bypass mucus, release drugs over time 3
Porcine Serum Available Anticoagulants: N-02: Citrate N-04: Heparin (Na) N-06: K2EDTA N-08: Potassium Oxalate N-10: EDTA (Na) N-03: Alsevers N-05: ACD N-07: CPD N-09: K3EDTA N-11...
Rat Normal Multiple Tissue Array 1 slide...
... other RNA precipitation methods in that it does ... the method of choice for removing inhibitors of ... LiCl precipitation may not remove all DNA contamination ... to be used for RT-PCR, it should be ...
...
Biology Products: